Biogen 4Q Revenues: $2.9 billion (+1%) 4Q Earnings: $649 million (-22%) FY Revenues: $11.4 billion (+6%) FY Earnings: $3.7 billion (+4%) Comments: Growth was driven by TECFIDERA revenues ($4.0 billion, up 9%); TYSABRI ($2.0 billion, up 4%); ELOCTATE ($513 million, up 61%); ALPROLIX ($334 million, up 42%); as well as BENEPALI, an etanercept biosimilar commercialized in Europe. Revenues were partially offset by a decrease in worldwide interferon sales. Earnings were negatively impac...